New Insights into Diabetic Polyneuropathy

JAMA

Volumn 290, Issue 10, 2003, Pages 1371-1376

  Polydefkis, Michael ^a   Griffin, John W ^a   McArthur, Justin ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE SEVERITY; DYSESTHESIA; ELECTROMYOGRAPHY; EVALUATION; FEMALE; FOOT; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LEG; NERVE CONDUCTION; NERVE FIBER; NERVE INJURY; NEUROLOGY; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; SENSORY NERVE; SKIN BIOPSY; SKIN TINGLING; SYMPTOMATOLOGY; TOE; BIOPSY; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DIAGNOSIS; GLUCOSE TOLERANCE TEST; INNERVATION; METABOLISM; MIDDLE AGED; NERVE REGENERATION; PATHOLOGY; SKIN;

BIOPSY; BLOOD GLUCOSE; CLINICAL TRIALS; CROSS-SECTIONAL STUDIES; DIABETIC NEUROPATHIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MIDDLE AGED; NERVE REGENERATION; SKIN;

EID: 0041411077     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.290.10.1371     Document Type: Article

References (62)

1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997;14 (suppl 5):S1-S85.
3. Fagot-Campagna A. Emergence of type 2 diabetes mellitus in children: epidemiological evidence. J Pediatr Endocrinol Metab. 2000;13(suppl 6):1395-1402.
4. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-824.
5. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabetes Metab. 1977;3:245-256.
6. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (2nd part) (author's transl)]. Diabetes Metab. 1977;3:173-182.
7. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author's transl)]. Diabetes Metab. 1977;3:97-107.
8. Kozak G, Rowbothan J. Diabetic foot disease: a major problem. In: Kozak G, Hoer C, eds. Management of Diabetic Foot Problems. Philadelphia, Pa: Saunders; 1984:1-8.
9. Caro J, Ward A, O'Brien J. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care. 2002;25:476-481.
10. Russell J, Feldman EL. Impaired glucose tolerance-does it cause neuropathy? Muscle Nerve. 2001;24:1109-1112.
11. McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology. 1995;45:1848-1855.
12. Kennedy WR, Wendelschafer-Crabb G. Utility of skin biopsy in diabetic neuropathy. Semin Neurol. 1996;16:163-171.
13. Kennedy W, Wendelschafer-Crabb G, Walk D. Utility of skin biopsy and skin blister in neurological practice. J Clin Neuromusc Dis. 2000;1:196-203.
14. Lauria G, Holland N, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy. J Neurol Sci. 1999;164:172-178.
15. Griffin JW, McArthur JC, Polydefkis M. Assessment of cutaneous innervation by skin biopsies. Curr Opin Neurol. 2001;14:655-659.
16. Bolton CF, Winkelmann RK, Dyck PJ. A quantitative study of Meissner's corpuscles in man. Neurology. 1966;16:1-9.
17. Dyck PJ, Winkelmann RK, Bolton CF. Quantitation of Meissner's corpuscles in hereditary neurologic disorders: Charcot-Marie-Tooth disease, Roussy-Levy syndrome, Dejerine-Sottas disease, hereditary sensory neuropathy, spinocerebellar degenerations, and hereditary spastic paraplegia. Neurology. 1966;16:10-17.
18. Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J. PGP 9.5-a new marker for vertebrate neurons and neuroendocrine cells. Brain Res. 1983;278:224-228.
19. Dalsgaard CJ, Rydh M, Haegerstrand A. Cutaneous innervation in man visualized with protein gene product 9.5 (PGP 9.5) antibodies. Histochemistry. 1989;92:385-390.
20. Wang L, Hilliges M, Jernberg T, Wiegleb-Edstrom D, Johansson O. Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res. 1990;261:25-33.
21. Kennedy WR, Wendelschafer-Crabb G. The innervation of human epidermis. J Neurol Sci. 1993;115:184-190.
22. McArthur JC, Stocks EA, Hauer P, Cornblath DR, Griffin JW. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol. 1998;55:1513-1520.
23. Kennedy WR, Wendelschafer-Crabb G, Johnson T. Quantitation of epidermal nerves in diabetic neuropathy. Neurology. 1996;47:1042-1048.
24. Polydefkis M, Yiannoutsos C, Cohen B, et al. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy. Neurology. 2002;58:115-119.
25. Holland NR, Stocks A, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Intraepidermal nerve fiber density in patients with painful sensory neuropathy. Neurology. 1997;48:708-711.
26. Herrmann DN, Griffin JW, Hauer P, Cornblath DR, McArthur JC. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology. 1999;53:1634-1640.
27. Holland NR, Crawford TO, Hauer P, Cornblath DR, Griffin JW, McArthur JC. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann Neurol. 1998;44:47-59.
28. Periquet MI, Novak V, Collins MP, et al. Painful sensory neuropathy: prospective evaluation using skin biopsy. Neurology. 1999;53:1641-1647.
29. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448-1453.
30. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve. 2001;24:1225-1228.
31. Sumner CJ, Sheth S, Griffin JW, Cornblath DR, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology. 2003;60:108-111.
32. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33-S49.
33. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
34. Tuomilehto J. Point: a glucose tolerance test is important for clinical practice. Diabetes Care. 2002;25:1880-1882.
35. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care. 1998;21:1236-1239.
36. Fisman E, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J. 2001;141:485-490.
37. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24:1448-1453.
38. Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229-1231.
39. Smith AG, Ramachandran P, Tripp S, Singleton JR. Epidermal nerve innervation in impaired glucose tolerance and diabetes-associated neuropathy. Neurology. 2001;57:1701-1704.
40. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-367.
41. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
42. Gordis L. Epidemiology. 2nd ed. Philadelphia, Pa: WB Saunders; 2000:184-203.
43. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes. 1997;46(suppl 2):S82-S89.
44. Pfeifer M, Schumer M. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes. 1995;44:1355-1361.
45. Low P. Experimental therapies of diabetes neuropathy. Paper presented at: Peripheral Nerve Society Meeting 2001; September 11, 2001; Tyrol, Austria.
46. Peripheral Nerve Society. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol. 1995;38:478-482.
47. Rajan B, Polydefkis M, Hauer PE, Griffin JW, McArthur JC. Epidermal reinnervation after intracutaneous axotomy in man. J Comp Neurol. 2003;457:24-36.
48. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997;389:816-824.
49. Wood JN, Winter J, James IF, Rang HP, Yeats J, Bevan S. Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J Neurosci. 1988;8:3208-3220.
50. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81:135-145.
51. Simone DA, Nolano M, Johnson T, Wendelschafer-Crabb G, Kennedy WR. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci. 1998;18:8947-8959.
52. Polydefkis M, Hauer P, Griffin J, McArthur J. A novel measure of human axonal regeneration for use in peripheral neuropathy trials. Neurology. 2003;60(5 suppl 1):A502.
53. Polydefkis M, Hauer P, Sheth S, et al. Experimental denervation of the epidermis demonstrates reduced regeneration of nociceptive fibers in people with diabetes. J Peripher Nerv Syst. 2003;8(suppl 1):1-78.
54. Kennedy JM, Zochodne DW. The regenerative deficit of peripheral nerves in experimental diabetes: its extent, timing and possible mechanisms. Brain. 2000;123:2118-2129.
55. Ozkul Y, Sabuncu T, Kocabey Y, Nazligul Y. Outcomes of carpal tunnel release in diabetic and non-diabetic patients. Acta Neurol Scand. 2002;106:168-172.
56. Haupt WF, Wintzer G, Schop A, Lottgen J, Pawlik G. Long-term results of carpal tunnel decompression: assessment of 60 cases. J Hand Surg Br. 1993;18:471-474.
57. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001;24:775-778.
58. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2003;26(suppl 1):33S-50S.
59. de Vegt F, Dekker J, Ruhe H, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
60. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PWF. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845-1850.
61. Jackson C, Yudkin J, Forrest R. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract. 1992;17:111-123.
62. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229-235.